Phanes Therapeutics

Executive Summary

Phanes Therapeutics is a private biotech company headquartered in San Diego, California, focused on innovative drug discovery and early development in immuno-oncology. Founded in 2018, the company leverages proprietary technologies to advance novel antibody-based biologics targeting challenging pathways in cancer immunotherapy. Despite its early stage and lack of disclosed pipeline details, Phanes has established a strong scientific foundation with a mission to become a major source of innovation in biopharma. The company operates in the competitive immuno-oncology space, aiming to differentiate through disruptive approaches to drug discovery. As a private entity, Phanes has not disclosed funding rounds or valuation, but its presence on biopharmguy suggests active engagement with the biotech ecosystem. The company's success hinges on advancing its preclinical candidates into clinical development, forming strategic partnerships, and securing additional financing to support its R&D pipeline.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing30% success
• Q3 2026Series A/B Financing Round50% success
• Q2 2027Research Partnership or Licensing Deal35% success